Plasminogen, fibrinogen, alpha 2-antiplasmin and antithrombin-III levels during a single cycle of a combined oral contraceptive regime
Baele, G.; Kaufman, J.M.; Thiery, M.; Vermeulen, A.; Barbier, F.
Acta Clinica Belgica 36(6): 280-285
1981
ISSN/ISBN: 1784-3286 PMID: 7331670 Document Number: 179675
Document emailed within 1 workday
Related Documents
Wolk, L.A.; Wilson, R.F.; Burdick, M.; Selik, N.; Brown, J.; Starricco, A.; Mammen, E.F. 1985: Changes in antithrombin, antiplasmin, and plasminogen during and after cardiopulmonary bypass American Surgeon 51(6): 309-313Ogawa, K.; Baba, S.; Funazaki, K.; Nakanishi, K.; Hirohashi, K.; Suzuki, E.; Tamura, M. 1984: The values of plasminogen, antithrombin III, factor XIIi and fibrinogen according to age and sex Rinsho Byori. Japanese Journal of Clinical Pathology 32(6): 679-682
Dabrowska, M.; Kemona, H.; Prokopowicz, J.; Kretowska, J.; Kiluk, S. 1991: Serum antithrombin IIi and alpha-2-antiplasmin concentrations in patients with Hodgkin's disease in the course of chemotherapy Neoplasma 38(3): 249-252
Aguilar Franco, C. 2004: Monitoring of antithrombin levels in women on oral contraceptive treatment Atencion Primaria 34(9): 508; Author Reply 508
Kotschy, M.; Drewniak, W.; Graczykowska-Koczorowska, A.; Listopadzki, D. 1992: Antithrombin IIi and alpha-2-antiplasmin activities compared with other hemostasis parameters in uncomplicated diabetes mellitus, type 2 Polski Tygodnik Lekarski 47(1-2): 17-18
Wong, K.K.; Ng, S.C.; Koong, P.L. 1992: Effect of the oral contraceptive pill on protein S and antithrombin-IIi levels in Malaysian women Medical Science Research 20(12): 439-440
Merz, M.; Kroll, R.; Lynen, R.; Bangerter, K. 2015: Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study Contraception 91(2): 113-120
Küçük, M.; Sezer, S.D.; Odabaşi, A.R.; Güner, Z.; Yuksel, H.; Serter, M. 2011: The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations Clinical and Experimental Obstetrics and Gynecology 38(1): 54-56
Fridrich, L.; Tuchmann, A.; Endler, T.; Meryn, S.; Moritz, E. 1983: Changes in fast antiplasmin (alpha-2-antiplasmin) activity of the plasma of thoracotomized patients Praxis und Klinik der Pneumologie 37 Suppl. 1: 742-744
Beck, K.J.; Weitzel, H. 1972: Changes of proteins in the cervical mucus following a single oral dose of 16 alpha ethylthioretroprogesterone during the pre-ovulatory phase of the menstrual cycle Geburtshilfe und Frauenheilkunde 32(7): 593-597
Bjarnadóttir, R.I.; Tuppurainen, M.; Killick, S.R. 2002: Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol American Journal of Obstetrics and Gynecology 186(3): 389-395
Hickey, M.; Agarwal, S. 2009: Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens Journal of Family Planning and Reproductive Health Care 35(4): 245-248
Bermejo, A.; Iglesias, C.; Ruiz-Alonso, M.ía.; Blesa, D.; Simón, C.; Pellicer, A.; García-Velasco, J. 2014: The impact of using the combined oral contraceptive pill for cycle scheduling on gene expression related to endometrial receptivity Human Reproduction 29(6): 1271-1278
Minozzi, M.; Costantino, D.; Guaraldi, C.; Unfer, V. 2011: The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 27(11): 920-924
Marr, J.; Niknian, M.; Shulman, L.P.; Lynen, R. 2011: Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen Contraception 84(1): 81-86
Bakas, P.; Hassiakos, D.; Grigoriadis, C.; Vlahos, N.F.; Liapis, A.; Creatsas, G. 2014: Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 30(11): 825-829
Lussier-Cacan, S.; Xhignesse, M.; Desmarais, J.L.; Davignon, J.; Kafrissen, M.E.; Chapdelaine, A. 1991: Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy Metabolism, Clinical and Experimental 40(8): 849-854
Zimmerman, Y.; Foidart, J.-M.; Pintiaux, A.; Minon, J.-M.; Fauser, B.C.J.M.; Cobey, K.; Coelingh Bennink, H.J.T. 2015: Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects Contraception 91(2): 127-133
Zimmerman, Y.; Foidart, J.-M.; Pintiaux, A.; Minon, J.-M.; Fauser, B.C.J.M.; Cobey, K.; Coelingh Bennink, H.J.T. 2015: Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects Contraception 91(2): 134-142
Liening, S.H.; Stanton, S.J.; Saini, E.K.; Schultheiss, O.C. 2010: Salivary testosterone, cortisol, and progesterone: two-week stability, interhormone correlations, and effects of time of day, menstrual cycle, and oral contraceptive use on steroid hormone levels Physiology and Behavior 99(1): 8-16